日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Weight Changes With Tirzepatide and Concomitant Weight-Inducing Medications: Post Hoc Analysis of Randomized Clinical Trials

替尔泽帕肽联合其他增重药物治疗对体重的影响:随机临床试验的事后分析

Galindo, Rodolfo J; Gudzune, Kimberly A; Look, Michelle; Lee, Clare J; Benabbad, Imane; Cao, Dachuang; Meng, Qier; Mojdami, Donna

Association of Tirzepatide With Kidney Parameters in Participants With Obesity and Prediabetes From SURMOUNT-1 Over 176 Weeks

SURMOUNT-1 研究中,Tirzepatide 与肥胖和糖尿病前期参与者肾脏参数的相关性(176 周)

Heerspink, Hiddo J L; van Raalte, Daniel H; Tuttle, Katherine; Cherney, David Z I; Bjornstad, Petter; Cao, Dachuang; Dimitriadis, Georgios K; Linetzky, Bruno; Jouravskaya, Irina; Bunck, Mathijs C; Griffin, Ryan; Gerber, Claire

Clinical impact and cost-effectiveness of rapid versus non-rapid antiretroviral therapy initiation in HIV-positive men who have sex with men in China using modelling and 96-week multicenter cohort data

利用模型和96周多中心队列数据,评估在中国男男性行为者中,快速启动与非快速启动抗逆转录病毒疗法的临床影响和成本效益

Zhou, Kejia; Wang, Xi; Zhou, Dachuang; Dai, Lili; Tang, Wenxi

Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT

替泽帕肽在肥胖且无已知重大精神病理学患者中的精神安全性:SURMOUNT 研究的事后分析

Wadden, Thomas A; Oquendo, Maria A; Kushner, Robert F; Cao, Dachuang; Karanikas, Chrisanthi A; Kechter, Afton; Murphy, Madhumita A

Nutritional status with tirzepatide in obesity: A post hoc analysis of the SURMOUNT-1-4 randomized clinical trials

替拉帕肽治疗肥胖症的营养状况:SURMOUNT-1-4 随机临床试验的事后分析

Almandoz, Jaime P; Pickett-Blakely, Octavia; Tewksbury, Colleen; Stefanski, Adam; Gonsahn-Bollie, Sylvia; Dimitriadis, Georgios K; Murro, Ada Leticia; Cao, Dachuang; Meng, Qier; Neff, Lisa M

People With Lowest Physical Functioning Scores Showed Greatest Improvement After Tirzepatide Treatment

接受替拉帕肽治疗后,身体机能评分最低的患者改善最为显著。

Li, Xuan; Cao, Dachuang; Sapin, Helene; Wang, Fangyu; Hunter Gibble, Theresa; Raibulet, Nedina Kalezic; Denning, Max; Kaplan, Lee M

Kidney Parameters with Tirzepatide in Obesity with or without Type 2 Diabetes

替拉帕肽治疗肥胖(伴或不伴2型糖尿病)患者的肾功能参数

Heerspink, Hiddo J L; Friedman, Allon N; Bjornstad, Petter; van Raalte, Daniel H; Cherney, David; Cao, Dachuang; Garcia-Pérez, Luis-Emilio; Stefanski, Adam; Turfanda, Ibrahim; Bunck, Mathijs C; Benabbad, Imane; Griffin, Ryan; Piras de Oliveira, Carolina

Association between weight reduction achieved with tirzepatide and quality of life in adults with obesity: Results from the SURMOUNT-1 study

替拉帕肽治疗肥胖成人患者体重减轻与生活质量之间的关联:SURMOUNT-1 研究结果

Gudzune, Kimberly A; Stefanski, Adam; Cao, Dachuang; Mojdami, Donna; Wang, Fangyu; Ahmad, Nadia; Ling Poon, Jiat

Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT-1 to -4 trials

在 SURMOUNT-1 至 -4 试验中,替尔泽帕肽在肥胖或超重成人(伴或不伴 2 型糖尿病)中的胃肠道耐受性和体重减轻情况

Rubino, Domenica M; Pedersen, Sue D; Connery, Lisa; Cao, Dachuang; Chigutsa, Farai; Stefanski, Adam; Fraseur Brumm, Julia; Griffin, Ryan; Gerber, Claire

Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight

在SURMOUNT-1研究中,使用替泽帕肽减轻体重期间肥胖或超重成年人的身体成分发生了变化

Look, Michelle; Dunn, Julia P; Kushner, Robert F; Cao, Dachuang; Harris, Charles; Gibble, Theresa Hunter; Stefanski, Adam; Griffin, Ryan